Adjuvant Epigenetic Therapy of Decitabine and Suberoylanilide Hydroxamic Acid Exerts Anti-Neoplastic Effects in Acute Myeloid Leukemia Cells

LAUR Repository

Show simple item record

dc.contributor.author Abou Najem, Sonia
dc.contributor.author Khawaja, Ghada
dc.contributor.author Hodroj, Mohammad Hassan
dc.contributor.author Babikian, Patil
dc.contributor.author Rizk, Sandra
dc.date.accessioned 2020-07-15T09:09:04Z
dc.date.available 2020-07-15T09:09:04Z
dc.date.copyright 2019 en_US
dc.date.issued 2020-07-15
dc.identifier.issn 2073-4409 en_US
dc.identifier.uri http://hdl.handle.net/10725/11976
dc.description.abstract Atypical epigenetic processes including histone acetylation and DNA methylation have been identified as a fundamental theme in hematologic malignancies. Such mechanisms modify gene expression and prompt, in part at least, the initiation and progression of several malignancies including acute myeloid leukemia. In the current study we determined the effects of treating KG-1 and U937 acute myeloid leukemia (AML) cells, in vitro, with the HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA), or with a DNMT inhibitor, decitabine (DAC), or their combination, on cell proliferation, cell cycle progression, apoptosis, and expression of apoptosis-related proteins. Each of SAHA and DAC attenuated cell proliferation and induced cell cycle arrest and apoptotic cell death of KG-1 and U937 cell lines. Besides, their sequential combination improved the obtained anti-neoplastic effect: significant augmentation of growth inhibition and apoptosis induction as compared to cells treated with either drug alone. This effect was featured by the upregulated expression of Bax, cytochrome c1, p21, and cleaved caspases 8, 9, and 3, signifying the activation of both the intrinsic and extrinsic pathways of apoptosis. The sequential combination of SAHA and DAC causes a profound antitumorigenic effect in AML cell lines by inducing the expression of tumor suppressor genes en_US
dc.language.iso en en_US
dc.title Adjuvant Epigenetic Therapy of Decitabine and Suberoylanilide Hydroxamic Acid Exerts Anti-Neoplastic Effects in Acute Myeloid Leukemia Cells en_US
dc.type Article en_US
dc.description.version Published en_US
dc.author.school SAS en_US
dc.author.idnumber 199829370 en_US
dc.author.department Natural Sciences en_US
dc.description.embargo N/A en_US
dc.relation.journal Cells en_US
dc.journal.volume 8 en_US
dc.journal.issue 12 en_US
dc.article.pages 1-23 en_US
dc.keywords Epigenetics en_US
dc.keywords Acute myeloid leukemia en_US
dc.keywords Decitabine en_US
dc.keywords Suberoylanilide hydroxamic acid en_US
dc.identifier.doi https://doi.org/10.3390/cells8121480 en_US
dc.identifier.ctation Abou Najem, S., Khawaja, G., Hodroj, M. H., Babikian, P., & Rizk, S. (2019). Adjuvant epigenetic therapy of decitabine and suberoylanilide hydroxamic acid exerts anti-neoplastic effects in acute myeloid leukemia cells. Cells, 8(12), 1-23. en_US
dc.author.email sandra.rizk@lau.edu.lb en_US
dc.identifier.tou http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php en_US
dc.identifier.url https://www.mdpi.com/2073-4409/8/12/1480 en_US
dc.orcid.id https://orcid.org/0000-0002-4405-5703 en_US
dc.author.affiliation Lebanese American University en_US

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account